Healthcare: Should You Stick With Gilead Sciences?

Industry Focus - A podcast by The Motley Fool

Categories:

Business

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD